Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Kaiyan Chen, Xiaoqing Yu, Zhiyu Huang, Yun Fan, Guoping Cheng, Yanjun Xu, Fanrong Zhang, Guanxia Zhu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with uncommon EGFR alterations was reported to derive clinical benefit from PD-1 blockade
Autor:
Aya Miyagawa-Hayashino, Masayoshi Inoue, Yuta Sonobe, Takahiro Yamada, Tadaaki Yamada, Satoru Okada, Masahiro Iwasaku, Koichi Takayama, Yusuke Chihara, Eiichi Konishi, Tatsuya Imabayashi, Takayuki Shimamoto, Yoshiko Kaneko, Akihiro Yoshimura, Junji Uchino
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 137
Objective Small cell lung cancer (SCLC), which accounts for approximately 15% of all lung cancer cases, has high initial sensitivity to chemotherapy. However, clinical outcomes have not improved in the past two decades. Therefore, novel biomarkers ar
Autor:
Kazuo Noguchi, Debra Kush, Yukio Hosomi, Gilberto Lopes, Kaname Nosaki, Gilberto de Castro, Yi-Long Wu, Martin Reck, Hideo Saka, Enriqueta Felip, Bilal Piperdi, Paul Baas, Takeshi Sawada, Julie R. Brahmer, Shi Rong Han
Publikováno v:
Ann Transl Med
Objectives Most lung cancer diagnoses occur in elderly patients, who are underrepresented in clinical trials. We present a pooled analysis of safety and efficacy in elderly patients (≥75 years) who received pembrolizumab (a programmed death 1 inhib
Autor:
Sukhmani K. Padda, Joseph B. Shrager, Summer S. Han, Joel W. Neal, Christian A. Kunder, Jacqueline V. Aredo, Heather A. Wakelee
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung cancer (NSCLC) and may differentially influence patient outcomes. We sought to characterize the effects of KRAS mutation subtypes and concurrent pathogenic mutations on ove
Autor:
Marc A. Schneider, Michael Meister, Thomas Muley, Achim Escherich, Felix J.F. Herth, Farshid Dayyani, Christa Stolp, Birgit Wehnl, Arne Warth, Vinzent Rolny, Ying He
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 130
Objectives The biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymis protein 4 (HE4) are useful in the diagnosis, prognosis, and monitoring of non-small cell lung cancer (NSCLC), but their combination has not been investigated yet. The
Autor:
Christian Asel, David Lang, Elmar Brehm, Klaus Langer, Bernhard Kaiser, Benedikt Hergan, Andreas Horner, Kaveh Akbari, Bernd Lamprecht, Mario Scala
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 134
To evaluate serum tumor markers (STM) as biomarkers for treatment monitoring and prognosis in advanced non-small cell lung cancer (NSCLC) treated with single-agent PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy.Carcinoembryonic antigen
Autor:
Franco Aversa, Matteo Goldoni, Marcello Tiseo, Francesco Facchinetti, Sebastiano Buti, Andrea Ardizzoni, Gabriele Missale, Alessandra Zecca, Denise Madeddu, Giulia Mazzaschi, Diana Canetti, Paola Bordi, Michele Veneziani, Francesco Gelsomino, Federico Quaini
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 127
Introduction: A prospective investigation of the circulating immune profile in NSCLC patients receiving nivolumab was performed to identify potentially predictive parameters. Methods: Flow Cytometry of peripheral blood (PB) CD3+, CD8+, CD4+, NK, Treg
Autor:
Keith L. Davis, Bruce E. Johnson, Christina S. Baik, Ken Culver, Patrick M. Forde, Leora Horn, Antoinette J. Wozniak, Alex Mutebi, Joshua Bauml, Medha Sasane, Heather A. Wakelee, Pingkuan Zhang, Nathaniel J. Myall, Anand A. Dalal
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 128
Introduction Clinical outcomes data on BRAF-mutated non-small cell lung cancer (NSCLC) patients treated in routine practice is limited. To address this gap, we described treatment patterns and survival in a cohort of these patients evaluated/treated
Autor:
Yosuke Dotsu, Makoto Nishio, Junji Koyama, Takahiro Yoshizawa, Shingo Nishikawa, Satoru Kitazono, Tomoaki Sonoda, Atsushi Horiike, Ryo Ariyasu, Noriko Yanagitani, Ken Uchibori, Masafumi Saiki
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Objective Serum adenosine deaminase (ADA) activity is a marker of immune reaction to several diseases. We evaluated changes in serum ADA in patients with lung cancer undergoing chemotherapy or anti-programmed cell death-1 (PD-1) therapy to examine th
Autor:
Gongyan Chen, Yiping Zhang, Jianhua Chen, Qiang Shi, Yong Song, Ping Yu, Yi Hu, Qing Zhou, Guosheng Feng, Zhuang Yu, Yi-Long Wu, Lu Jing Zhan, Xia Song, Xin Zhang, Luan Di Yao, Lu Lu Yang, Dian-Sheng Zhong, Fan Yang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 123
Objectives This study investigated factors associated with (i) the likelihood of receiving a gene aberration test and (ii) the choice of treatment between chemotherapy and targeted therapy in patients with non-small cell lung cancer (NSCLC) in China.